Marc Cobo - 21 Oct 2026 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
23 Oct 2026, 16:15:04 UTC
Prior SEC filing
05 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Aaron Chan, Attorney-in-Fact
Filing notes and source

Key filing fact

Marc Cobo filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (BBOT) on 23 Oct 2026.

Key facts

  • This page summarizes Marc Cobo's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (BBOT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 23 Oct 2026, 16:15.

Change

  • Previous filing in this sequence was filed on 05 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001816654 Primary reporting owner

Cobo Marc

Relationship
Principal Accounting Officer
Address
BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Signature
/s/ Aaron Chan, Attorney-in-Fact
Signature date
23 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBOT transaction

Common Stock

Tax liability

Transaction value
Shares
-203
Change %
-1.4%
Price
$2.68*
Shares after
13,812
Date
21 Oct 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .